Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | HTR7 | P34969 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.59 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8009539 | 0.91 | MAPT (0.79) | KCNH2MAPTHTR7ALOX15KMT2A | |
| SCHEMBL25097473 | 0.91 | MAPT (0.79) | KCNH2MAPTHTR7ALOX15KMT2A | |
| SCHEMBL8002897 | 0.91 | MAPT (0.79) | KCNH2MAPTHTR7ALOX15KMT2A | |
| SCHEMBL12576551 | 0.90 | MAPT (0.83) | KCNH2MAPTHTR7ALOX15KMT2A | |
| SCHEMBL2016631 | 0.89 | KCNH2 (0.88) | KCNH2MAPTHTR7KMT2AMAPK1 | |
| SCHEMBL2016634 | 0.89 | KCNH2 (0.88) | KCNH2MAPTHTR7KMT2AMAPK1 | |
| SCHEMBL2016628 | 0.89 | KCNH2 (0.88) | KCNH2MAPTHTR7KMT2AMAPK1 | |
| SCHEMBL8002620 | 0.88 | KCNH2 (0.74) | KCNH2MAPTHTR7ALOX15KMT2A | |
| SCHEMBL23097675 | 0.88 | KCNH2 (0.74) | KCNH2MAPTHTR7ALOX15KMT2A | |
| SCHEMBL25097472 | 0.86 | MEN1 (0.81) | KCNH2MAPTHTR7ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| WO-2009137843-A2 | NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | EMORY UNIVERSITY (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | KCNH2 135/4885MAPT 2536/4885HTR7 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.